Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Capital Expenditures (2020 - 2024)

Gain Therapeutics (GANX) has 5 years of Capital Expenditures data on record, last reported at $945.0 in Q4 2024.

  • For Q4 2024, Capital Expenditures rose 4873.68% year-over-year to $945.0; the TTM value through Dec 2024 reached $1615.0, down 89.48%, while the annual FY2024 figure was $22493.0, 46.46% up from the prior year.
  • Capital Expenditures reached $945.0 in Q4 2024 per GANX's latest filing, up from $1.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $57179.0 in Q3 2022 and bottomed at -$38.0 in Q2 2020.
  • Average Capital Expenditures over 5 years is $13905.3, with a median of $8611.5 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: skyrocketed 59318.42% in 2021, then tumbled 99.85% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $14551.0 in 2020, then decreased by 23.73% to $11098.0 in 2021, then dropped by 15.32% to $9398.0 in 2022, then crashed by 99.8% to $19.0 in 2023, then surged by 4873.68% to $945.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $945.0 in Q4 2024, $1.0 in Q3 2024, and $19.0 in Q4 2023.